Weekly Docetaxel Plus Cisplatin as the First-line Therapy for Nasopharyngeal Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2011 by Samsung Medical Center.
Recruitment status was  Recruiting
Information provided by:
Samsung Medical Center
ClinicalTrials.gov Identifier:
First received: February 21, 2011
Last updated: March 8, 2011
Last verified: March 2011
The investigators will evaluate weekly docetaxel plus 3-weekly cisplatin regimen as the first-line therapy for recurrent of metastatic nasophayngeal cancer

Condition Intervention Phase
Nasopharyngeal Cancer
Drug: Docetaxel, Cisplatin
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Trial of Cisplatin Plus Weekly Docetaxel as the First-line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Resource links provided by NLM:

Further study details as provided by Samsung Medical Center:

Primary Outcome Measures:
  • objective response rate [ Time Frame: 6 months after the enrollment of the last patients ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • number of patients with adverse events [ Time Frame: simultaneously when the analysis of primary endpoint ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 51
Study Start Date: July 2006
Estimated Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: weekly docetaxel and cisplatin
Docetaxel 35mg/m2 D1 & D8 Cisplatin 70mg/m2 D1 every 3 weeks maxinum 6 cycles
Drug: Docetaxel, Cisplatin
Docetaxel 35mg/m2 D1 & D8 Cisplatin 70mg/m2 D1


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • histologically confirmed nasopharyngeal cancer
  • chemotherapy or radiotherapy naive (but, including patients completed 6 months before the enrollment)
  • ECOG 0-1
  • at least one measurable lesion

Exclusion Criteria:

  • other cancer
  • pregnat
  • docetaxel hypersentitivity history
  • severe heart or pulmonary disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01312311

Contact: Myung-Ju Ahn, Pf 82-2-3410-3459 silkahn@skku.edu

Korea, Republic of
Samsung Medical Center Recruiting
Seoul, Korea, Republic of, 135-710
Contact: Myung-Ju Ahn, Pf    822-3410-3459    silkahn@skku.edu   
Sponsors and Collaborators
Samsung Medical Center
  More Information

Responsible Party: Myung-Ju Ahn / Professor, Samsung Medical Center
ClinicalTrials.gov Identifier: NCT01312311     History of Changes
Other Study ID Numbers: 2006-07-005 
Study First Received: February 21, 2011
Last Updated: March 8, 2011
Health Authority: South Korea: Korea Food and Drug Administration (KFDA)

Keywords provided by Samsung Medical Center:
nasopharyngeal cancer
weekly docetaxel

Additional relevant MeSH terms:
Nasopharyngeal Neoplasms
Head and Neck Neoplasms
Nasopharyngeal Diseases
Neoplasms by Site
Otorhinolaryngologic Diseases
Otorhinolaryngologic Neoplasms
Pharyngeal Diseases
Pharyngeal Neoplasms
Stomatognathic Diseases
Antimitotic Agents
Antineoplastic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Tubulin Modulators

ClinicalTrials.gov processed this record on May 24, 2016